We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.80 | 1.93% | 201.00 | 199.20 | 203.50 | 202.50 | 194.20 | 199.00 | 240,015 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.31 | 194.61M |
TIDMOXB
Oxford Biomedica PLC
31 March 2017
Hardman Research: Delivering commercial gene-therapy vector
Delivering commercial gene-therapy vector - OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector(R) platform: extensive IP, facilities, and know-how for production and development of lentivirus vectors to generate gene-based therapies. OXB intends to out-license its five clinical candidates and to continue investment in R&D. Bioprocessing royalties are likely to result in significant upside potential in the near future.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf
To contact us: Contacts: Hardman & Co Dr Martin Hall 11/12 Tokenhouse mh@hardmanandco.com Yard Dr Dorothea Hill London dmh@hardmanandco.com EC2R 7AS Dr Gregoire Pave gp@hardmanabdco.com Telephone: +44 20 7929 3399 Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAJMMRTMBMJBBR
(END) Dow Jones Newswires
March 31, 2017 02:15 ET (06:15 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions